Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company based in San Diego, California, founded in 1992. The company focuses on developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. It went public in 1996 and has since evolved into a leader in addressing unmet medical needs in these areas. The company's flagship product is valbenazine (Ingrezza), which received FDA approval in 2017 for treating tardive dyskinesia, a neurological movement disorder. Neurocrine is also engaged in research and development of innovative therapies for various conditions, including anxiety, depression, irritable bowel syndrome, obesity, and Alzheimer's disease. The company collaborates with notable partners such as Janssen Pharmaceutica, Eli Lilly, GlaxoSmithKline, and AbbVie to enhance its research and commercialization efforts.